Barron’s mentions:
Pfizer (NYSE:PFE) is the subject of the cover story this week with the stock called attractive after the sharp share price drop. Despite the drop in revenue after vaccine sales slowed, analysts think the pipeline is strong enough to support a bounce back. Key launches include vaccines for the respiratory syncytial virus, or RSV, meningitis, and the flu, and drugs to treat atopic dermatitis and multiple myeloma. Pfizer is also noted to have made the strategic move to offset patent losses in 2025 to 2028 through acquisitions for companies such as Arena Pharmaceuticals, Biohaven Pharmaceuticals, and Global Blood Therapies. The drug giant is estimated to be only 40% on the way to meeting its goal of $25B in revenue from acquired drugs in 2030. On a valuation basis, Pfizer trades at a 13X multiple and sports a well-protected dividend yield of 3.72%.